Q1FY22 Result Update - Dr Reddy's Laboratories - ICICI Direct

Dr Reddy's reported weak margins in its Q1FY22 results.

- Sales were up 11.7% YoY to Rs. 4945.1 crore

- EBITDA in Q1FY22 was at Rs. 734 crore, down 34% YoY with margins at 15%

- Consequent PAT was at Rs. 380.4 crore (down 36% YoY)

Key triggers for future price performance

- Decent US pipeline - 93 ANDAs & three NDAs pending for approval; 47 are Para IV and the management believes 24 have first to file status

- Pricing pressure on some key products - Atrovastatin, Metoprolol, Liposomal Doxorubicin, Buprenorphine and Naloxone

- Near term triggers - Ramp up of Sputnik V vaccine and Revlimid launch

- Focus on cost rationalisation, especially on SG&A front and endeavour to focus on simultaneous launches across geographies

For details, click on the link below: Link to the report

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs. 4712.7 as compared to the previous close of Rs. 4671.05. The total number of shares traded during the day was 59196 in over 7953 trades.

The stock hit an intraday high of Rs. 4802 and intraday low of 4679.9. The net turnover during the day was Rs. 281011593.

Source : Equity Bulls

Keywords